ArticleSleep2010
Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy.
Article in Sleep, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 130 citations in OpenAlex.
- Narcolepsy is (not) an autoimmune disease.Nature reviews. Neurology · 2026Review
- Immunocyte phenotypes underlying the causal autoimmune features in narcolepsy type 1.Journal of thoracic disease · 2026Article
- Increased neutrophil-to-lymphocyte ratio as a possible marker to detect neuroinflammation in patients with narcolepsy type 1.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025Article
- Cell-based vs enzyme-linked immunosorbent assay for detection of anti-Tribbles homolog 2 autoantibodies in Chinese patients with narcolepsy.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2024Article
- The immunopathogenesis of narcolepsy type 1.Nature reviews. Immunology · 2024Review
- Narcolepsy-A Neuropathological Obscure Sleep Disorder: A Narrative Review of Current Literature.Brain sciences · 2022Review
- Narcolepsy: a model interaction between immune system, nervous system, and sleep-wake regulation.Seminars in immunopathology · 2022Review
- Reviewing the Clinical Implications of Treating Narcolepsy as an Autoimmune Disorder.Nature and science of sleep · 2021Review
- Heterogeneity of Hypocretin/Orexin Neurons.Frontiers of neurology and neuroscience · 2021Review
- Immunotherapy in Narcolepsy.Current treatment options in neurology · 2020Review
- Post-infectious neurological disorders.Therapeutic advances in neurological disorders · 2020Review
- No evidence of autoimmunity to human OXJournal of translational autoimmunity · 2020Article
- HLA-DQB1*06:02 allele frequency and clinic-polysomnographic features in Saudi Arabian patients with narcolepsy.Sleep & breathing = Schlaf & Atmung · 2019Article
- Genetics of narcolepsy.Human genome variation · 2019Review
- Article
- Narcolepsy Associated with Pandemrix Vaccine.Current neurology and neuroscience reports · 2018Review
- Autoimmunity in narcolepsy.Current opinion in pulmonary medicine · 2017Review
- Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.CNS drugs · 2017Review
- Is it Time for Immunotherapy Trials in Narcolepsy?Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2017Article
- Intravenous Immunoglobulin Therapy in Pediatric Narcolepsy: A Nonrandomized, Open-Label, Controlled, Longitudinal Observational Study.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2017Observational
Corrections and comments
- Commented on by
Authors and funding
8 authors at 7 institutions in 5 countries.
Funding
Abstract
STUDY
objectiveRecent studies have found increased autoantibodies against Tribbles homolog 2 (anti-TRIB2) and anti-streptolysin O (ASO) in narcolepsy. In this study, we replicated this finding with a primary focus on recent onset cases. PARTICIPANTS AND
methodsParticipants included (1) 90 cases with cataplexy, (2) 57 cases without cataplexy, and (3) 156 age-sex matched controls, including 73 human leukocyte antigen (HLA)-DQB1*0602 allele carriers. A radioligand binding assay was used to detect anti-TRIB2 antibodies.
resultsAnti-TRIB2 antibodies were prevalent in HLA-DQB1*0602 positive cases with cataplexy (25.0% of 76) and rare in cases without cataplexy (3.5% of 57, OR = 9.2, 95% CI = 2.5 - 33.5, P = 6.0 x 10(-4)) or controls (4.5% of 156, OR = 7.1, 95% CI = 3.1 - 16.2, P = 9.3 x 10(-6)). Anti-TRIB2 positivity in controls was not associated with DQB1*0602. In DQB1*0602 narcolepsy-cataplexy cases, the presence of anti-TRIB2 was associated with short disease duration (2.3 years from cataplexy onset), with 41.0% positive in this group (OR = 7.4 versus cases with onset > 2.3 years, 95% CI = 1.9- 28.5, P = 9.0 x 10(-4)). Anti-TRIB2 positivity in 39 DQB1*0602 positive recent onset cases was associated with increased ASO antibody (> 200 IU) (OR = 6.2, 95% CI = 1.6 - 24.6, P = 0.01), but did not correlate with age, gender, or body mass index.
conclusionAnti-TRIB2 autoantibodies are strongly associated with narcolepsy close to cataplexy onset (< or = 2.3 years). Anti-TRIB2 was rarely found in cases without cataplexy or with distant onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.